Company intelligence / Profile preview

CellCure Neurosciences Ltd.

Jerusalem, Jerusalem Area, Israellineagecell.com ↗

Ownership: Private
Employees: ~8
Development stage: Phase 2

Overview

OpRegen, their lead product, is in Phase 2a development for the treatment of geographic atrophy secondary to age-related macular degeneration, now under a worldwide collaboration with Roche and Genentech. Preclinical data showed OpRegen RPE cells survived, rescued visual function, and preserved rod and cone photoreceptors long-term in animal models[8].

Therapeutic areas: OphthalmologyNeurology
Modalities: Cell therapyHuman embryonic stem cells (hESCs)
Industry: Biotech

Drug pipeline

1 asset

OpRegen

Phase 2

Indications: Geographic atrophy, Dry age-related macular degeneration

Partnerships

Teva PharmaceuticalsRoche/Genentech

Beyond the preview

Go deeper on CellCure Neurosciences Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellCure Neurosciences Ltd..

Explore the full profile